Sonova held back due to loss of Costco contract

The Swiss hearing aid manufacturer describes losing one of its ”largest customers in the US” while noting a general deceleration of the pace of the US market.

by marketwire, translated by christian radich hoffman

Swiss Sonova – which as the world’s biggest hearing aid manufacturer competes with Demant, GN Hearing and WSA – concluded its fiscal year of 2022/2023 with overall results below expectations.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

Access all locked articles

Receive our daily newsletters

Access our app

Get full access for you and your coworkers

Start a free company trial today

Sonova forecasts growth next fiscal year despite short-term uncertainties
For subscribers
Sonova beats back, regains veterans market shares in April
For subscribers
Over-the-counter hearing aids behind 1% of first-quarter sales in US
For subscribers

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Pharma & biotech

CHMP recommends 14 new medicines in July

The Alzheimer’s treatment lecanemab has not received a recommendation this time around. Seven brand new treatments and seven generics and biosimilars have received such treatment.

Leo Pharma receives positive CHMP opinion of treatment for chronic hand eczema

CHMP recommends ten new medicines in June

For subscribers

Pharma & biotech

Leo Pharma receives positive CHMP opinion of treatment for chronic hand eczema

For subscribers

Genmab is collaborating with US Abbvie on the development of cancer drug Epkinly. | Foto: Medwatch/photo by Ulrich Quistgaard

Pharma & biotech

Genmab's cancer hope continues to show solid growth rates

For subscribers

Pharma & biotech

Preliminary investigation points to "heat generation in machine" as cause of fire at Novo Nordisk site

For subscribers

Pharma & biotech

Fire department extinguishes minor fire at Novo Nordisk

For subscribers

Violet Zahedi is co-founder and CEO of Synamics Therapeutics, which is developing an artificial intelligence-driven drug discovery platform for cancer drug discovery. | Foto: Synamics Therapeutics / Jeffrey Hunter / Easy Communications / PR

Pharma & biotech

Cancer company receives investment from former Novozymes executives

For subscribers

Foto: Gonzalo Fuentes/Reuters/Ritzau Scanpix

Sanofi raises forecast for 2024 after strong quarter

Sanofi now expects a flat growth in adjusted earnings per share in constant currencies, where it previously expected a low single-digit decline.

For subscribers

Roche adjusts upwards after Q2 progress

Roche now expects revenue to grow mid-single digits and adjusted earnings per share to grow high single digits by 2024.

Foto: Hannah Beier/Reuters/Ritzau Scanpix

Novo Nordisk receives UK approval for Wegovy for cardiovascular disease

Authorities in the UK have now approved the drug to prevent heart problems in obese people.

Demant's share price drops after downward adjustment is over, says Jyske Bank

Jyske Bank believes that Demant now seems to have factored in something close to a worst-case scenario at the low end of the guidance range.

Novo Holdings at the forefront of triple-digit million investment

US-based Magenta Medical has developed the world’s smallest heart pump, according to Novo Holdings.

For subscribers

Biogen hit by global IT crash - Novo Nordisk and Eli Lilly unscathed

Novo Nordisk and Eli Lilly have reported normal operations during the IT outage.

For subscribers

Genmab's cancer hope continues to show solid growth rates

Epkinly sales reached new heights in the second quarter.

For subscribers

Hearing health

Demant's share price drops after downward adjustment is over, says Jyske Bank

Jyske Bank believes that Demant now seems to have factored in something close to a worst-case scenario at the low end of the guidance range.

Pharma & biotech

CHMP recommends 14 new medicines in July

The Alzheimer’s treatment lecanemab has not received a recommendation this time around. Seven brand new treatments and seven generics and biosimilars have received such treatment.

For subscribers

Pharma & biotech

Fire department extinguishes minor fire at Novo Nordisk

The cause of a fire in a basement at Novo Nordisk in the Danish city of Måløv on Wednesday afternoon is not yet known, the police informs.

For subscribers

Pharma & biotech

Leo Pharma receives positive CHMP opinion of treatment for chronic hand eczema

Based on the JAK inhibitor delgocitinib, Anzupgo could be the first topical treatment specifically approved for adults with CHE where topical corticosteroids are insufficient, says Leo Pharma.

For subscribers

For months, Renovaro Biosciences highlighted an upcoming Dutch acquisition. Today, however, according to the co-founder of the targeted "leading" company, the deal has been called off. (ILLUSTRATION) | Foto: Generated by DALL·E

Medtech

Dutch company dismisses acquisition announcement from Danish-based medtech company

Renovaro Biosciences announced earlier this year that new acquisitions were on the horizon. However, negotiations have now been called off. Top management remains silent.

For subscribers